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ABSTRACT: A series of 3-amino-2-hydroxybenzofused 2-phosphalactones (4a−l) has been synthesized from the Kabachnik−
Fields reaction via a facile route from a one-pot three-component reaction of diphenylphosphite with various 2-hydroxybenzaldehyes
and heterocyclic amines in a new way of expansion. The in vitro anti-cell proliferation studies by MTT assay have revealed them as
potential Panc-1, Miapaca-2, and BxPC-3 pancreatic cell growth inhibitors, and the same is supported by molecular docking, QSAR,
and ADMET studies. The MTT assay of their SAHA derivatives against the same cell lines evidenced them as potential HDAC
inhibitors and identified 4a, 4b, and 4k substituted with 1,3-thiazol, 1,3,4-thiadiazol, and 5-sulfanyl-1,3,4-thiadiazol moieties on
phenyl and diethylamino phenyl rings as potential ones. Additionally, the flow cytometric analyses of 4a, 4b, and 4k against BxPC-3
cells revealed compound 4k as a lead compound that arrests the S phase cell cycle growth at low micromolar concentrations. The
ADMET properties have ascertained their inherent pharmacokinetic potentiality, and the wholesome results prompted us to report it
as the first study on anti-pancreatic cancer activity of cyclic α-aminophosphonates. Ultimately, this study serves as a good
contribution to update the existing knowledge on the anticancer organophosphorus heterocyclic compounds and elevates the scope
for generation of new anticancer drugs. Further, the studies like QSAR, drug properties, toxicity risks, and bioactivity scores
predicted for them have ascertained the synthesized compounds as newer and potential drug candidates. Hence, this study had
augmented the array of α-aminophosphonates by adding a new collection of 3-amino-2-hydroxybenzofused 2-phosphalactones, a
class of cyclic α-aminophosphonates, to it, which proved them as potential anti-pancreatic cancer agents.
■ INTRODUCTION
Organophosphorus chemistry has offered many catalysts for
the successful accomplishments of complex1 and coupling2
reactions by the action of potential catalyst promoters.3 In
medicinal perspectives, some of them have been identified as
potential antioxidant,4 antifungal,5 antibacterial,6−8 antidia-
betic,9 anticancer,10 antithrombotic,11 and antimicrobial12
agents. Their re-emergence in the field of medicinal chemistry
made it amplified as many of them were impregnated with
potential moieties in its design itself13 and identified with a
wide array of applications.14 α-Aminophosphoryl functionality
on a pharmacophoric core promotes antitumor activity15 and
strongly inhibits the human tumor growth and induces
apoptosis via the mitochondria-dependent pathway16 on safe
and non-toxic grounds without affecting the normal cells.17
The recent reports on the biological activity evaluation studies
of organophosphorus heterocycles reveal that this is a search
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thrust area with perpetual contributions.18 Such inherent
anticancer potentiality of α-aminophosphonates19−25 has
inspired us to design and synthesize some new 3-amino
functionalized benzofused phospha-γ-lactones with a potential
core of the 2,5-dihydro-1,2-oxaphosphole-2-oxide moiety26
and investigate their pancreatic cell inhibition activity.
Meanwhile, the previous methodologies for the synthesis of
benzofused 2-phospha-γ-lactones involves the utility of
precursors like aldols,27 divinyl ethers,26 acetylene carboxylic
acids,26 chalcones,26 allenes,28,29 and alkynyl systems30−34
along with phosphorylating agents like dichlorophenylphos-
phines,32,35,36 dichlorophenyl phosphineoxides,37 triphenyl
phosphine,31,34 trialkylphosphite,38 3-methylbuta-1,2-dien-1-
ylphosphonic dichlorides,39 allenyl phosphonates,40 and dialkyl
phosphites.33,41 The present route for the synthesis of 2,5-
dihydro-1,2-oxaphosphole-2-oxide core is highly adaptable
with simple reaction procedures and hence eliminates the
use of expensive precursors (Figure 1).
As phospha-coumaranones (phospha-γ-lactones) are ana-
logues of coumaranones (coumaran derivatives) by structure
and as coumaranones are potential antiplasmodial,42 anti-
fungal,43 anti-neoplasia,44 and anticancer45 agents, we have
designed the synthesis of their phosphorus analogues bearing a
cyclic phosphonic acid group (hydroxy group located on the
phosphoryl group), which easily facilitates ring opening
operations in vivo metabolic processes (hydrolysis) and
hence acts as potential prodrugs.46 This has motivated us to
investigate the anti-pancreatic cancer activity and to identify
the mechanistic aspects of cell cycle inhibition. Ultimately,
authors have synthesized the title compounds and reported 4k
with 5-sulfanyl-1,3,4-thiadiazolyl, and diethylamino phenyl
rings interlinked by an aminophosphoryl moiety is identified
as potential inhibitors against S (synthesis) phase cell cycle
inhibition as ascertained by flow cytometry studies at low
micromolar concentrations. The literature study reveals that
this is the first contribution on the anti-pancreatic cancer
activity of phospha-γ-lactones having a cyclic aminophospo-
nate moiety.
■ RESULTS AND DISCUSSION
Chemistry. The synthesis of novel 3-amino-substituted
benzofused 2-phospha-γ-lactones derivatives (4a−l) with a
core of 3-heteroarylamino-substituted-1,2-oxaphopholicacids
has been accomplished by a facile one-pot three-component
reaction of various 2-hydroxybenzaldehyes, heterocyclic
amines, and diphenyl phosphite (Scheme 1). The regular
mechanistic approach of the Kabachnik−Fields reaction for the
synthesis of α-aminophosphonate (I) from aldehyde, amine,
and phosphite has been expanded as such its aryloxy oxygen
internally attacks on phosphoryl phosphorus and forms the
phospha-γ-lactone monoester (II) at elevated temperatures. In
the next step, the liberated water of the reaction hydrolyzes the
monoester (II) at the same elevated temperatures and
ultimately forms the phospha-γ-lactone (III) as designed and
as shown in the plausible mechanism (Figure 2). It is observed
that the conversion of II to III was successful simply with the
prolonged heating and does not need any external reagent and
catalyst. Hence, this one-pot three-component single-step
methodology has been identified as a cost-effective and step-
economic reaction to offer phospha-γ-lactones in short
reaction times.
The key mechanistic facet directing the design and synthesis
of 2-hydroxy phospha-γ-lactones is the presence of the o-
hydroxy group on aryl aldehyde and re-consumption of the
liberated water into the reaction. The scope of the formation of
Figure 1. Methods for the synthesis of phospha-γ-lactones.
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phospha-γ-lactones from the expansion of Kabachnik−Fields
reaction has been investigated with various phosphites like
dimethylphosphite, diethylphosphite, di-i-propylphosphite,
dibutylphosphite, di-t-butylphosphite, and dibenzylphosphite
along with diphenylphosphite under same reaction conditions.
However, none of them have resulted a phospha-γ-lactone
monoester or its acid except diphenylphosphite, which is a
product-specific reaction with respect to diphenylphosphite
(Figure 3).
In productivity point, nitro-substituted salicylaldehyde has
offered high product yields when compared to diethylamino-
substituted salicylaldehyde and unsubstituted salicylaldehyde.
Similarly, the reactivity of amines has also followed an order
that thiazol-2-amine had offered the high product yields and
1,3,4-thiadiazol-2-amine, 1H-1,2,4-triazol-3-amine, and 5-
amino-1,3,4- thiadiazole-2-thiol are aligned in the sequence
of decreasing product yields. Studies in varying salicylalde-
hydes and amines are currently under study for further
exploration of their synthetic utility in order to evaluate their
anti-cell proliferation activities against other cancer cell lines.
The chemical structures of 4a−l were established by IR, 1H,
13C, and 31P NMR spectral and mass spectrometric studies and
elemental analyses. IR absorptions were observed at 3433−
3416, 1238−1222, and 1096−1076 cm−1 for NH, PO, and
P−O stretching vibrations.47,48 Two 1H NMR singlet
characteristic peaks for −NH−CH− (C-3) proton at δ
3.98−3.93 and for −NH−CH− (C-10) proton at δ 4.28−
4.24 were observed.48,49 The 13C characteristic peak for P−CH
(C-3) carbon was observed at δ 74.6−63.2.48,49 The 31P
characteristic peaks were observed as singlet at δ 19.58−16.36
for PO.48 The mass spectra of 4a−l confirmed significant
molecular and daughter ion peaks at expected m/z values.
Cytotoxicity Assay. Compounds 4a−l were screened in
vitro for pancreatic cancer cell inhibition assay on BxPC-3
(Table 1), Miapaca-2 (Table 2), Panc-1 (Table 3), and Panc-1
with SAHA (suberoyl + anilide + hydroxamic acid) bound
(Table 4) cell lines, and the results are presented in Tables
1−4, respectively. The anticancer activity of 4a−l and their
SAHA-treated models were assessed by MTT assay with
increasing concentrations. Treating of BxPC-3 cells with 4a−l
revealed that 4a, 4b, and 4k have arrested the cell proliferation
dose dependently and are identified as potential inhibitors at
50 μM/L (maximum effective concentration) and inhibited the
BxPC-3 cell growth to greater than 50%. The % of cell survival
profiles of compound 4k (BxPC-3, Miapaca-2, and Panc-1)
and its SAHA derivative (Panc-1 cells) is presented in Figure 4.
The results of cytotoxicity assay have provided a rationale for
further studies on HDAC inhibition and other human
pancreatic malignancies viz., Panc-1, Miapaca-2, and BxPC-3,
and hence we have performed the cell cycle analysis for the
potential compounds 4a, 4b, and 4k.
S Phase Cell Cycle Arrest. In understanding the mode of
the mechanism by which compounds 4a, 4b, and 4k are
regulating the growth and proliferating the BxPC-3 cells, we
have performed the flow cytometric cell cycle analysis on
treated BxPC-3 cells and identified that the treatment of 4k
resulted in an increased percentage of cells in the S phase of
the cell cycle compared to DMSO control [4k (G0/G1 phase:
45.5 ± 0.6; S phase: 27.2 ± 0.7; G2/M phase: 26.7 ± 0.2) and
DMSO control (G0/G1 phase: 69.70 ± 0.6; S phase: 13.0 ±
0.2; G2/M phase: 16.9 ± 0.4)] (Figure 5). This has suggested
that 4k suppresses the BxPC-3 cell cycle progress into next
phases by regulating the S phase, where compounds 4a and 4b
are identified as comparatively less significant and identified 4k
as a potential lead compound.
Molecular Docking Studies. Molecular docking proper-
ties of 4a−l have evolved from the selective protein of the
pharmacological target regulating the cell proliferation of the
pancreatic cancer cell lines. The H-bond interactions of 4a−l
with cancer therapeutic targets formed among H-bond
acceptors and donors (Acc and Don), H-bond acceptors
(Acc), and aromatic centers (Aro) in the substructure of the
tryptophan moiety and phosphate moiety against the arene−
cation and arene−arene interactions against the functional
groups located on the residues of the inhibitor binding sites,
sustaining the downregulation of signaling of the cancer cell by
profoundly inhibiting and inactivating the target protein, which
is a vital task. The two-dimensional ligand−receptor
interaction representation maps are shown in Figure 6.
The ligand data was predicted for the novel ligands
(molecules) bound to the proteins that were docked at the
target-specified binding domains of the 3HNC receptor.
Cumulatively, more than 30 conformations were captured for
each ligand−receptor complex pair. Among these binding
conformations, the confirmation with the least docking score
was taken into account of the study. Where the identified
Scheme 1. Synthesis of 3-Amino-Substituted Benzofused
Phosphalactone Derivatives
Figure 2. Mechanism for the synthesis of phospha-γ-lactones.
Figure 3. Scope of expansion of the Kabachnik−Fields reaction.
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interactions are hydrophobic in major and the protein−ligand
interactions at the binding domain cavity were studied from
ligand interaction studies on molecular operating environment
(MOE) software. The study revealed that all compounds are
well interacted with the specified proteins of the target cells in
the binding domains of the human ribonucleotide reductase,
and this study has helped to identify the human ribonucleotide
reductase inhibitors; the data is presented in Tables 5 and 6.
The in silico study performed has helped to screen a large
number of newly proposed compounds to assess the potential
inhibitory activity theoretically by docking onto the selected
targets. The resulted docking scores and modules infer us to
proceed for in vitro assays for a validated cell inhibitory activity.
Ultimately, the more stabilized conformations have been
further considered for studying QSAR (quantitative structure−
activity relationship) descriptors followed by Lipinski filtration
to identify drug likeliness and interactions of 4a−l with novel
inhibitors with the ABAD active site.
The molecular docking of 4a−l against the human
ribonucleotide reductase active site (PDB ID: 3HNC) revealed
the arene−arene interactions of 4a, 4c, and 4h with Tyr625,
PO interactions of 4b with Asn144, P−OH interactions of
4b with Gln609, 4e and 4f with Glu615, thiadiazolic sulfur
interactions of 4c with Thr626, 4j with Phe146 and 4g with
Table 1. Percentage of BxPC-3 Cell Survival Studies
concentrations
entry 3.125 μM 6.25 μM 12.5 μM 25.0 μM 50.0 μM IC50 (μg/mL)
4a 71.88 ± 0.36 64.91 ± 0.57 54.35 ± 0.69 48.32 ± 0.82 37.99 ± 1.13 27.72
4b 77.27 ± 0.16 69.30 ± 0.34 60.34 ± 0.51 56.46 ± 0.79 45.98 ± 0.93 39.64
4c 80.54 ± 1.17 73.49 ± 0.62 68.44 ± 0.54 62.75 ± 0.33 57.78 ± 1.14 62.97
4d 90.32 ± 0.84 81.26 ± 0.38 77.42 ± 0.49 65.28 ± 0.51 52.36 ± 0.84 53.90
4e 95.03 ± 1.07 89.11 ± 0.80 85.63 ± 0.91 82.61 ± 0.75 71.22 ± 0.21 96.40
4f 95.25 ± 0.23 87.63 ± 0.35 78.17 ± 0.48 69.28 ± 0.19 60.49 ± 0.38 60.62
4g 96.73 ± 0.24 91.71 ± 0.12 87.56 ± 0.54 79.95 ± 0.39 72.53 ± 0.69 92.83
4h 98.54 ± 0.58 99.48 ± 0.17 93.72 ± 0.42 92.70 ± 0.81 84.22 ± 0.73 159.55
4i 93.28 ± 0.77 88.45 ± 0.82 79.66 ± 0.52 68.14 ± 0.89 59.79 ± 0.27 59.46
4j 97.62 ± 0.59 86.40 ± 0.45 78.23 ± 0.19 66.38 ± 1.10 56.38 ± 0.86 53.25
4k 59.79 ± 1.25 51.64 ± 1.16 39.73 ± 0.94 40.79 ± 1.06 39.05 ± 0.89 8.48
4l 91.22 ± 0.95 85.36 ± 0.76 76.54 ± 0.83 61.22 ± 0.61 55.67 ± 0.87 51.68
Table 2. Percentage of MiaPaca-2Cell Survival Studies
concentrations
entry 3.125 μM 6.25 μM 12.5 μM 25.0 μM 50.0 μM IC50 (μg/mL)
4a 85.63 ± 1.28 79.40 ± 0.96 72.33 ± 0.89 61.44 ± 0.37 51.42 ± 0.49 48.19
4b 81.37 ± 1.02 77.61 ± 0.88 70.45 ± 0.24 63.65 ± 0.72 53.27 ± 0.56 52.83
4c 91.54 ± 0.87 87.69 ± 0.85 77.18 ± 0.67 64.60 ± 0.57 59.37 ± 0.78 57.74
4d 92.38 ± 0.76 85.75 ± 0.84 73.58 ± 0.62 65.64 ± 0.45 60.82 ± 0.52 60.74
4e 94.63 ± 0.77 86.22 ± 0.86 79.59 ± 0.75 73.30 ± 0.68 66.29 ± 0.58 75.70
4f 97.72 ± 0.76 91.53 ± 0.88 86.66 ± 0.45 81.36 ± 0.36 75.43 ± 0.39 105.37
4g 96.15 ± 1.26 93.39 ± 0.99 89.15 ± 0.87 83.06 ± 0.65 80.47 ± 0.71 138.35
4h 93.19 ± 0.43 91.11 ± 0.68 88.09 ± 0.72 82.84 ± 0.57 79.78 ± 0.31 151.61
4i 94.72 ± 0.77 86.65 ± 0.85 79.47 ± 0.96 72.54 ± 0.63 65.42 ± 0.72 72.68
4j 95.61 ± 1.32 88.29 ± 1.09 82.54 ± 0.26 77.54 ± 0.78 71.65 ± 0.53 93.48
4k 82.97 ± 0.78 76.51 ± 0.98 70.78 ± 0.65 63.77 ± 0.83 55.67 ± 0.54 56.73
4l 99.76 ± 0.98 92.35 ± 0.54 86.54 ± 0.49 81.78 ± 0.67 74.32 ± 0.59 96.95
Table 3. Percentage of PANC-1Cell Survival Studies
concentrations
entry 3.125 μM 6.25 μM 12.5 μM 25.0 μM 50.0 μM IC50 (μg/mL)
4a 90.99 ± 0.96 86.24 ± 0.82 75.58 ± 0.54 67.54 ± 0.66 61.04 ± 0.90 62.72
4b 94.27 ± 0.67 88.03 ± 0.94 78.73 ± 1.14 66.95 ± 0.81 62.49 ± 0.75 62.89
4c 97.51 ± 0.92 89.65 ± 0.87 82.84 ± 0.76 76.98 ± 0.85 73.43 ± 0.69 95.68
4d 98.67 ± 0.72 96.14 ± 0.69 91.36 ± 0.44 89.76 ± 0.58 84.11 ± 0.85 167.34
4e 99.45 ± 0.25 98.65 ± 0.37 96.88 ± 0.36 92.13 ± 0.42 87.99 ± 0.53 199.09
4f 95.08 ± 0.76 92.45 ± 0.64 90.43 ± 0.78 88.67 ± 0.28 84.37 ± 0.87 215.66
4g 99.07 ± 0.62 95.92 ± 0.54 89.84 ± 0.48 87.07 ± 0.32 84.90 ± 0.45 170.87
4h 99.48 ± 0.54 97.56 ± 0.65 94.39 ± 0.49 91.50 ± 0.37 87.04 ± 0.53 194.23
4i 94.15 ± 0.77 90.56 ± 0.65 85.65 ± 0.72 79.43 ± 0.58 74.16 ± 0.43 105.15
4j 93.56 ± 0.68 88.97 ± 0.73 83.56 ± 0.89 78.85 ± 0.96 75.36 ± 0.99 116.22
4k 79.18 ± 0.42 76.84 ± 0.58 74.34 ± 0.55 67.73 ± 0.63 63.12 ± 0.39 85.02
4l 93.89 ± 0.52 87.75 ± 0.56 81.43 ± 0.65 78.36 ± 0.43 72.55 ± 0.29 102.29
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Gln609 and Thr150, arene−H interactions of 4f and 4j with
Gln609, thiadiazole ring−arene interactions of 4f with Tyr625,
thiadiazolic−SH interactions of 4g with Arg628 and Thr150,
thiazole ring−H interactions of 4h with Asn614, triazolic−NH
interactions of 4h with Thr621, triazole ring mediated −P−
CH−NH interactions of 4h with Glu615, and −NO2
interactions of 4h and 4f with Tyr625, which confirms their
docking modes with target receptor proteins. Similarly, the
molecular docking of 4a−l against histone deacetylase
(HDAC, PDB ID: 4LXZ) revealed the PO interactions of
4a, 4d, and 4l with His142, 4e with His180, 4g and 4k with
Tyr100, 4h with His142, 4i with Lys33, 4j with Tyr306, and 4k
with Tyr100, −P(O)OH interactions of 4b and 4h with
Asp178, 4g, 4i, and 4l with Tyr100, 4h with Asp267, 4k with
Lys33, thiadiazolic−N3 interactions of 4a with arene-mediated
Phe208 and His180, 4e with Phe152, 4e, 4f, and 4j with
Asp101 and Phe208, thiadiazole−arene interactions of 4j with
Phe208 and Asp101, triazole ring−arene interactions of 4d, 4h,
and 4l with Phe152, 4h and 4l with His180, P(O)−O−CAr
interactions of 4f with His180, thiadiazolic−2-SH-mediated
arene interactions of 4g with Phe152 and Asp101, triazolic−5-
NH interactions of 4h with Tyr306, diethylamino methylic−
arene interactions of 4i with Phe208, P(O)−O−CAr ring
interactions of 4j with His180, and 2-mercapto thiadiazole−
arene interactions of 4k with Phe152 and Asp101, which
confirms their docking with target receptors.
In continuation, the molecular docking analysis of SAHA
derivatives of 4a−l against histone deacetylase (HDAC, PDB
ID: 4LXZ) revealed the main interactions viz., C(O)−NH−
interactions (4a and 4b: Tyr306, 4d: Phe208, 4e: Asp101, 4g:
His143, 4i: Tyr100, and 4l: Tyr306), −O−NH− interactions
Table 4. Percentage of PANC-1Cell Survival Studies with SAHA Derivatives
concentrations
entry 3.125 μM 6.25 μM 12.5 μM 25.0 μM 50.0 μM IC50 (μg/mL)
4a 90.76 ± 0.95 83.52 ± 0.54 75.77 ± 1.06 63.93 ± 0.87 58.42 ± 0.72 57.08
4b 92.61 ± 0.46 84.88 ± 0.59 76.86 ± 0.73 64.87 ± 0.63 57.67 ± 0.78 55.66
4c 93.78 ± 1.27 85.69 ± 0.19 74.36 ± 0.49 67.58 ± 0.23 63.92 ± 0.57 67.21
4d 94.42 ± 0.78 88.69 ± 0.65 81.93 ± 0.52 76.58 ± 0.37 72.66 ± 0.48 218.16
4e 99.91 ± 0.85 96.33 ± 0.56 94.25 ± 0.79 92.18 ± 0.83 89.71 ± 0.65 258.74
4f 99.41 ± 0.38 97.75 ± 0.54 96.13 ± 0.42 94.76 ± 0.37 91.85 ± 0.59 332.59
4g 98.02 ± 0.55 91.15 ± 0.73 89.60 ± 0.41 88.04 ± 0.39 85.50 ± 0.65 221.08
4h 95.71 ± 0.48 91.58 ± 0.43 89.13 ± 0.37 88.01 ± 0.62 86.05 ± 0.53 262.37
4i 99.54 ± 0.75 95.69 ± 0.66 90.47 ± 0.62 88.89 ± 0.59 85.97 ± 0.79 188.16
4j 97.33 ± 0.98 93.67 ± 0.87 89.43 ± 0.76 84.69 ± 0.65 79.54 ± 0.93 129.54
4k 88.15 ± 0.65 82.26 ± 0.48 74.86 ± 0.35 66.52 ± 0.39 54.92 ± 0.52 54.31
4l 99.87 ± 0.63 93.14 ± 0.87 87.28 ± 0.74 82.27 ± 0.35 77.54 ± 0.72 110.24
Figure 4. Effect of 4k and 4k+SAHA against BxPC-3, Panc-1 and
Miapaca-2, and Panc-1 cells.
Figure 5. Effects of title compounds on the cell cycle of BxPC-3.
Figure 6. Two-dimensional ligand−receptor interaction representa-
tion maps.
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(4a, 4b, and 4h: Asp101, 4d: His180, 4f: Phe208, and 4f and 4
h: Phe152), arene interactions (4c: His180, 4g: Lys33), 2-
mercapto thiadiazolic interactions (4c: Asp101), 2-mercapto
thiadiazolic−arene interactions (4c: Phe152), P−O−CAr
interactions (4c: Tyr306), PO interactions (4d: Tyr306,
4h: Lys33, and 4k: Tyr100), triazole−arene interactions (4d:
Phe152), triazolic−NH interactions (4d: Gly151, 4l: Asp101),
thiadiazole interactions (4e: Asp101), thiadiazolic S-arene
interactions (4e: Phe152), thiadiazole arene interactions (4f:
Phe208), thiazolic N interactions (4i: Asp101), thiazolic N-
arene interactions (4i: Phe208), thiazolic NH interactions (4i:
Gly151), thiazolic NH-arene interactions (4i: Phe152),
diethylamino methyl interactions (4i and 4j: Asp267 and
Asp178), diethylamino methyl−arene interactions (4i and 4j:
His142), and thiadiazolic S interactions (4j: Asp101) with
target receptors (Table 7).
ADMET Properties. ADMET (absorption, distribution,-
metabolism, and excretion) properties of 4a−l revealed 4a, 4b,
and 4i−l as potent and 4c−h are moderate with intestinal
absorption, and all have medium permeability for in vitro Caco-
2 cells, low permeability for in vitro MDCK cells, low
absorption with in vivo blood−brain barrier (BBB) penetration
capacity, and supported them as CNS-active compounds as
they are penetrable to BBB. The extent of plasma protein
binding (PPB) of a compound stimulates the drug action as
well as the compound’s disposition and efficacy. Based on the
ADMET properties, the percentage of drug compound bound
with plasma proteins was envisioned and here compounds 4c,
4g, and 4i−l were strongly bound, whereas compounds 4a, 4b,
4d, 4e, and 4f are identified as weakly bound to plasma
proteins (Table 8).
QSAR Studies. The understanding of chemical interactions
of compounds with the anticipated pharmacological target
helps in ascertaining their use as potential drugs.50,51 Hence,
the prediction of molecular descriptors for 4a−l from the
QSAR study proved them as safer drugs in acceptable range of
values. The molecular weights of 4a−l are less than 500
Table 5. Molecular Docking Interaction of 4a−l against
Human Ribonucleotide Reductase Active Site
aentry
bdocking
score cno. H bonds dinteracting residues of ABAD
4a −4.936 arene interaction Tyr 625
4b −4.543 1 Gln 609
4c −5.075 2 Try 625, Thr 626
4d −4.187 1 Asn 144
4e −5.212 1 and 3 Gln 615 and Gln 615, Try 625, Gln
609
4f −5.589 arene interaction Try 625
4g −5.303 4 Arg 628, 2 (Thr 150), Gln 609
4h −5.361 3 and arene
interaction
Glu 615, Thr 621, Tyr 625 and Asn
614, Tyr 625
4i −5.212
4j −5.873 2 Phe 146, Gln 609
4k −5.352
4l −5.271
aThe novel 3HNC inhibitors. bDocking scores predicted from MOE
docking in binding domain of docked novel leads and ribonucleotide
reductase proteins. cNumber of hydrogen bonds formed in binding
domain among ribonucleotide reductase and the novel leads. dThe
active site residues interacting among ribonucleotide reductase
protein and the novel inhibitors in the ligand−receptor complex of
the study.
Table 6. Molecular Docking Interactions 4a−l with 3HNC
Protein at the Human Ribonucleotide Reductase Active Site
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Daltons and logP values below 5 units govern themselves in a
safe manner with an in vivo host. The number of hydrogen
bond acceptors and donors present in them strengthens the
formation of the best ligand−receptor complex pair. The
congruent sum-up of these parameters persuades Lipinski’s
rule of five and ascertains their inherent pharmacological
potentiality. Their surface area and volume values ensure their
absorption and distribution in the best interaction with the
host system.
Other parameters like gradient energy and total energy have
confirmed the establishment of their interactions with receptor
proteins and their capability to fit into the target’s binding
cavity. Ultimately, the binding region of the receptor protein,
volume, molar refractivity, hydration energy, polarizability, and
conformation has empowered the interaction of 4a−l with the
receptor. In support of in vitro studies, the 2D-QSAR studies
were accomplished by using the three eigenvectors (PCA1,
PCA2, and PCA3) and their linear regression studies are
plotted in Figure 7 and noticed that the most potent curves are
identified nearer the correlation curve; the molecular
descriptors are shown in Table 9. The 2D-QSAR analysis
revealed that all the values are laid in the +3 to −3 range, and
the study supported the effective drug properties of 4a, 4b, and
4k (Figure 8).
Bioactivity and Toxicity Risk Studies. The bioactivity
study results revealed them as potential inhibitors toward ion
channel modulator and G protein-coupled receptor ligand and
also proved them as good inhibitors of protease, kinase,
enzyme, and nuclear receptor ligand. Similarly, they are good
with drug score and drug-likeness values along with the
hydration energy gradient energy and total energy values. The
Table 7. Comparative Protein−Ligand Binding Properties of 4a−l and Their SAHA Derivatives
docking score binding energy binding affinity Pki efficiency
entry pure compound SAHA derivative pure compound SAHA derivative pure compound SAHA derivative pure compound SAHA derivative
4a −12.5 −11.9 −18.7 −28.9 10.2 11.70 0.605 0.335
4b −13.8 −11.7 −19.0 −7.70 10.4 10.70 0.612 0.306
4c −12.0 −12.0 −9.40 10.20 8.20 11.20 0.459 0.314
4d −14.6 −13.0 −23.0 −19.80 8.70 11.17 0.517 0.319
4e −10.0 −10.7 −9.22 495.0 6.05 2.700 0.303 0.070
4f −13.2 −12.3 −7.30 −28.04 8.46 10.90 0.420 0.289
4g −12.1 −13.0 −0.949 −30.2 8.10 11.02 0.390 0.290
4h −13.5 −13.8 −19.80 −24.7 9.40 11.42 0.474 0.300
4i −11.0 −12.5 −14.20 −29.4 6.60 12.20 0.302 0.305
4j −13.3 −13.4 −5.90 −22.46 9.90 14.30 0.434 0.359
4k −11.6 −12.4 −5.80 12.50 7.60 9.600 0.334 0.230
4l −14.0 −15.25 −12.1 −37.044 9.80 12..88 0.448 0.322





in vitro Caco-2 cell
permeability
(nm/sec)b









in vivo blood−brain barrier
penetration (C.brain
/C.blood)f toxicityg
4a 86.3824 1.3408 26.8358 −3.7287 82.6676 0.2629 negative
4b 75.6539 0.4007 21.2933 −4.1593 83.0199 0.1383 negative
4c 64.2959 0.3780 32.3669 −3.6705 99.0693 0.1129 negative
4d 65.52749 0.3749 10.6479 −4.4693 73.3206 0.3142 negative
4e 44.9103 0.3733 1.5565 −3.5385 84.2593 0.0980 negative
4f 28.6676 0.3736 0.8129 −3.8568 81.0702 0.0685 negative
4g 20.0169 0.3695 0.7395 −3.5409 99.7054 0.0593 negative
4h 20.8803 0.3673 1.2663 −4.1431 67.6284 0.3162 negative
4i 92.1140 18.2471 69.1110 −2.9966 100.0000 0.4244 negative
4j 85.3032 5.3632 52.2455 −3.3667 100.0000 0.2141 negative
4k 76.8665 1.4893 10.7085 −3.1303 100.0000 0.1683 negative
4l 76.0095 1.1041 82.9175 −3.8803 97.1879 0.1495 negative
aHIA is the sum of bioavailability and absorption evaluated from the ratio of excretion or cumulative excretion in urine, bile, and feces. bCaco-2
cells are derived from human colon adenocarcinoma and possess multiple drug transport pathways through the intestinal epithelium. cMDCK cell
system is used as a tool for rapid permeability screening. dThe in vitro skin permeability infers the transdermal drug delivery property. eThe percent
of drug binds to plasma protein. fBlood−brain barrier (BBB) = [brain]/[blood]. gIn vitro Ames test by metabolic and non-metabolic activated
TA100 and TA1535 strains collected from rat liver homogenate.
Figure 7. Linear correlation curves of the synthesized compounds.
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toxicity risk analysis reveals them as negative toward
mutagenic, tumorigenic, irritant (Table 10), and reproductive
effects and supports them as drug proficient compounds.
■ CONCLUSIONS
Synthesis of a class of 3-amino-2-hydroxybenzofused 2-
phospha-γ-lactones (4a−l) has been accomplished and
reported them as potential Panc-1, Miapaca-2, and BxPC-3
pancreatic cell growth inhibitors from the in vitro anti-
pancreatic cell proliferation assay and from the predicted
molecular docking and 3D-QSAR properties. In addition, the
MTT assay performed for the prepared SAHA derivatives of
4a-l has also supported them as potential anti-pancreatic
cancer active compounds and also identified them as potential
histone deacetylase (HDAC) inhibitors. The potential anti-
pancreatic cancer cell proliferative activity identified from the
cell cycle analysis of 4k by flow cytometry at low micromolar
concentrations prompted the authors to report the title
compounds as potential inhibitors as ascertained by the S
phase cell cycle arrest. This significant rationale has enriched
our study to develop some more new 3-amino-2-hydrox-
ybenzofused 2-phospha-γ-lactones and to report them as
potential HDAC inhibitors. Ultimately, this study will
definitely enhance the research thrust in the development of
new and innovative medicinal applications of organophospho-
rus heterocycles as anticancer agents. Explicitly, these detailed
biological studies surely help in developing new organo-
phosphorus heterocycles and establishing their structure−
reactivity relationship and will pave the way for the discovery
of newer drugs.
■ EXPERIMENTAL SECTION
General. Chemicals, reagents, and solvents were procured
from Merck, where the solvents used for spectroscopy and
other characterization of studies were reagent grade. NMR
spectra were recorded on a Bruker instrument at 400 MHz for
1H NMR and 100 MHz for 13C NMR in CDCl3 solution using
TMS as an internal standard. Chemical shifts were given in
ppm, and coupling constants (J) were given in Hz. LCMS mass
spectral characterization was performed by using a Jeol SX 102
DA/600 mass spectrometer; FTIR spectral analysis was
performed on Bruker Alpha featured with an EcoATR
interferometer equipped with a single reflection sampling
module and ZnSe crystal, and absorption maxima readings
were given in wavenumbers (cm−1). Melting points were
recorded on EZ-Melt automated equipment.
Chemistry. Title compounds (4a−l) were synthesized by
reacting 0.10 mL of 2-hydroxybenzaldehye (1.0 mmol), 0.10 g
of 2-aminothiazole (1.0 mmol), and 0.23 mL of diphenyl-
phosphite (1.2 mmol) in 6 mL of toluene in a 50 mL flask
fitted with a reflux condenser, the contents were refluxed to
completion of the reaction by TLC monitoring (3:7 ratio of
ethyl acetate and hexane), and the reaction was completed by
the product formation after 3 h of refluxing. After completion
of the reaction, contents of the flask were cooled to room
temperature, then added 5 mL of methanol, and then filtered.
The filtered residue was washed with 5 mL of methanol four
times and then purified on a chromatographic column and
collected the solid in pure form and then dried in a vacuum
Table 9. Molecular Descriptors of Compounds 4a−l from the QSAR Studya













of H V.Vol. ρ S CLP % ABS P
4a 268.23 5 2 1.32 63.62 0 71.45 2 0 19 168.53 1.59 −2.69 0.17 84.35 22.84
4b 269.22 6 2 0.98 61.42 0 84.34 2 0 17 201.59 1.66 −2.13 −0.5 79.90 22.87
4c 301.29 6 2 1.50 69.27 0 84.35 2 0 18 219.25 1.71 −3.85 −0.01 79.89 25.73
4d 252.17 7 3 0.04 57.21 0 100.14 2 0 16 195.86 1.66 −2.18 −1.32 74.45 36.90
4e 313.23 8 2 1.26 69.66 0 117.28 3 0 18 229.08 1.73 −3.15 −0.76 68.53 25.26
4f 314.22 9 2 0.92 67.46 0 130.17 3 0 16 224.92 1.81 −2.59 −1.42 64.10 24.25
4g 346.29 9 2 1.44 75.30 0 130.16 3 0 17 242.58 1.85 −4.31 −0.93 64.09 27.55
4h 297.17 10 3 −0.02 63.24 0 145.96 3 0 15 219.20 1.82 −2.64 −2.24 58.64 22.91
4i 339.36 6 2 2.15 86.02 0 74.69 5 0 32 285.25 1.41 −3.33 0.88 83.23 32.24
4j 340.35 7 2 1.81 83.82 0 87.58 5 0 30 281.10 1.46 −2.77 0.21 78.78 34.53
4k 372.41 7 2 2.33 91.67 0 87.59 5 0 31 298.76 1.51 −4.48 0.74 78.77 34.56
4l 323.29 8 3 0.87 79.60 0 103.87 5 0 29 275.37 1.45 −2.82 −0.61 73.16 29.88
aMW: molecular weight; HB Don: hydrogen bond donors (n ON); HB Acc: hydrogen bond acceptors (n OH NH); logP: log of octanol to water
partition coefficient; MR: molecular refractivity (cm3/mol); Lip. Vio.: Lipinski violations; TPSA: total polar surface area (A°)2; no. of RB: number
of rotatable bonds; Veb. Vio.: Veber violations; no. of “H”: number of hydrophobic atoms; V.vol.: van der Waals volume; ρ: density (g/cc); S:
solubility; CLP: ClogP; % ABS: % of absorption; P: polarizability (Ao3).
Figure 8. 2D-QSAR principal component analysis (PCA) plots of
compounds 4a−l against the BxPC-3 cell.
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oven to get 4a in pure form. Similarly, the remaining
compounds 4b−l were synthesized by varying the substrate
and they were structurally ascertained by the spectral and
elemental characterization studies.
2-Hydroxy-3-(1,3-thiazol-2-ylamino)-2,3-dihydro-1,2λ5-
benzoxaphosphol-2-one (4a). Brownish pink solid, yield:
79.2%, mp: 285−287 °C; IR (ZnSe) ν (cm−1): 1076 (P−O),
1225 (PO), 3427 (N−H); 1H NMR (400 MHz, DMSO-d6)
δ: 3.98 (s, 1H, H-3), 4.25 (s, 1H, H-10), 6.77 (d, 1H, H-12),
6.90−6.84 (m, 2H, H-5, and H-7), 7.09−7.03 (m, 2H, H-4,
and H-6), 7.24 (d, 1H, H-13) ppm; 13C NMR (100 MHz,
DMSO-d6) δ: 64.3 (C-3), 112.5 (C-13), 119.4 (C-7), 121.2
(C-5), 128.2 (C-6), 128.4 (C-4), 129.8 (C-8), 137.2 (C-14),
155.6 (C-9), 163.4 (C-11) ppm; 31P NMR (160 MHz,
DMSO-d6) δ: 17.69 ppm; ESI MS m/z: 537.1 [2 M + H]
+,
269.2 [M + H]+; anal. calcd for C10H9N2O3PS: C, 44.78; H,
3.38; N, 10.44. Found: C, 44.60; H, 3.33; N, 10.38.
2-Hydroxy-3-(1,3,4-thiadiazol-2-ylamino)-2,3-dihydro-
1,2λ5-benzoxaphosphol-2-one (4b). Pale pink solid, yield:
75.7%, mp: 269−271 °C; IR (ZnSe) ν (cm−1): 1085 (P−O),
1239 (PO), 3417 (N−H); 1H NMR (400 MHz, DMSO-d6)
δ: 3.97 (s, 1H, H-3), 4.24 (s, 1H, H-10), 6.92−6.86 (m, 2H,
H-5, and H-7), 7.08−7.02 (m, 2H, H-4, and H-6), 8.75 (s, 1H,
H-13) ppm; 13C NMR (100 MHz, DMSO-d6) δ: 64.1 (C-3),
119.5 (C-7), 121.3 (C-5), 128.4 (C-6), 128.2 (C-4), 129.9 (C-
8), 152.3 (C-13), 156.7 (C-9), 164.3 (C-11) ppm; 31P NMR
(160 MHz, DMSO-d6) δ: 16.56 ppm; ESI MS m/z: 539.5 [2
M + H]+, 270.2 [M + H]+; anal. calcd for C9H8N3O3PS: C,
40.15; H, 3.00; N, 15.61. Found: C, 39.97; H, 2.95; N, 15.48.
2-Hydroxy-3-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)amino]-
2,3-dihydro-1,2λ5-benzoxaphosphol-2-one (4c). Reddish
pink solid, yield: 69.2%, mp: 257−259 °C; IR (ZnSe) ν
(cm−1): 1089 (P−O), 1229 (PO), 3420 (N−H); 1H NMR
(400 MHz, DMSO-d6) δ: 3.25 (s, 1H, C13-SH), 3.94 (s, 1H,
H-3), 4.25 (s, 1H, H-10), 6.93−6.87 (m, 2H, H-5, and H-7),
7.07−7.03 (m, 2H, H-4, and H-6) ppm; 13C NMR (100 MHz,
DMSO-d6) δ: 64.3 (C-3), 119.6 (C-7), 121.7 (C-5), 128.4 (C-
6), 128.6 (C-4), 129.7 (C-8), 156.4 (C-9), 164.6 (C-11), 179.3
(C-13) ppm; 31P NMR (160 MHz, DMSO-d6) δ: 17.94 ppm;
ESI MS m/z: 602.6 [2 M + H]+; 301.8 [M + H]+; anal. calcd
for C9H8N3O3PS2: C, 35.88; H, 2.68; N, 13.95. Found: C,
35.63; H, 2.62; N, 13.82.
2-Hydroxy-3-(1H-1,2,4-triazol-3-ylamino)-2,3-dihydro-
1,2λ5-benzoxaphosphol-2-one (4d). White solid, yield:
73.6%, mp: 285−287 °C; IR (ZnSe) ν (cm−1): 1089 (P−
O), 1237 (PO), 3429 (N−H); 1H NMR (400 MHz,
DMSO-d6) δ: 3.96 (s, 1H, H-3), 4.25 (s, 1H, H-10), 6.93−
6.87 (m, 2H, H-5, and H-7), 7.09−7.03 (m, 2H, H-4, and H-
6), 7.63 (s, 1H, H-14), 12.85 (s, 1H, C14-NHAr) ppm;
13C
NMR (100 MHz, DMSO-d6) δ: 64.5 (C-3), 119.3 (C-7),
121.4 (C-5), 128.3 (C-6), 128.6 (C-4), 129.9 (C-8), 146.3 (C-
14), 156.2 (C-9), 163.6 (C-11) ppm; 31P NMR (160 MHz,
DMSO-d6) δ: 18.89 ppm; ESI MS m/z: 505.1432 [2 M + H]
+,
253.0715 [M + H]+; anal. calcd for C9H9N4O3P: C, 42.87; H,
3.60; N, 22.22. Found: C, 42.58; H, 3.55; N, 22.10.
2-Hydroxy-5-nitro-3-(1,3-thiazol-2-ylamino)-2,3-dihydro-
1,2λ5-benzoxaphosphol-2-one (4e). Brownish yellow solid,
yield: 86.5%, mp: 237−239 °C; IR (ZnSe) ν (cm−1): 1078
(P−O), 1218 (PO), 3417 (N−H); 1H NMR (400 MHz,
DMSO-d6) δ: 3.98 (s, 1H, H-3), 4.26 (s, 1H, H-10),6.78 (d,
1H, H-13), 7.12 (d, 1H, H-7), 7.28 (d, 1H, H-14), 7.94 (d,
1H, H-6), 7.98 (s, 1H, H-4) ppm; 13C NMR (100 MHz,
DMSO-d6) δ: 63.4 (C-3), 112.3 (C-13), 116.7 (C-7), 124.3
(C-6), 124.9 (C-4), 130.6 (C-8), 137.3 (C-14), 140.5 (C-5),
162.3 (C-9), 163.4 (C-11) ppm; 31P NMR (160 MHz,
DMSO-d6) δ: 16.36 ppm; ESI MS m/z: 625.8 [2 M + H]
+;
313.9 [M + H]+; anal. calcd for C10H8N3O5PS: C, 38.35; H,
2.57; N, 13.42. Found: C, 38.12; H, 2.53; N, 13.32.
2-Hydroxy-5-nitro-3-(1,3,4-thiadiazol-2-ylamino)-2,3-di-
hydro-1,2λ5-benzoxaphosphol-2-one (4f). Pale brown solid,
yield: 83.7%, mp: 249−251 °C; IR (ZnSe) ν (cm−1): 1081
(P−O), 1226 (PO), 3416 (N−H); 1H NMR (400 MHz,
DMSO-d6) δ: 3.98 (s, 1H, H-3), 4.27 (s, 1H, H-10), 7.05 (d,
1H, H-7), 7.92 (d, 1H, H-6), 7.96 (s, 1H, H-4), 9.25 (s, 1H,
H-13) ppm; 13C NMR (100 MHz, DMSO-d6) δ: 63.4 (C-3),
116.7 (C-7), 124.5 (C-6), 124.6 (C-4), 130.2 (C-8), 140.7 (C-
5), 152.4 (C-13), 162.3 (C-9), 164.5 (C-11) ppm; 31P NMR
(160 MHz, DMSO-d6) δ: 19.58 ppm. ESI MS m/z: 628.4 [2
M + H]+; 314.7 [M + H]+; anal. calcd for C9H7N4O5PS: C,
34.40; H, 2.25; N, 17.83. Found: C, 34.13; H, 2.19; N, 17.70.
2-Hydroxy-5-nitro-3-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)-
amino]-2,3-dihydro-1,2λ5-benzoxaphosphol-2-one (4g). Yel-
low solid, yield: 79.1%, mp: 224−226 °C; IR (ZnSe) ν (cm−1):
1084 (P−O), 1226 (PO), 3422 (N−H); 1H NMR (400
MHz, DMSO-d6) δ: 3.32 (s, 1H, C13-SH), 3.98 (s, 1H, H-3),
Table 10. Bioactivity Scores, Drug Properties, and Toxicity Risks of 7a−sa
bioactivity drug properties energy parameters toxicity risks
entry GPCRL ICM KI NRL PI EI drug-likeness drug score H.E. G.E. T.E. Mut Tum Irrit R.E.
7a −0.27 0.19 0.09 −0.40 0.25 0.45 −23.67 0.46 −19.14 0.091 73.50 Nil Nil Nil Nil
7b −0.51 −0.02 −0.11 −0.27 0.05 0.31 −23.16 0.28 −19.15 0.093 73.51 Nil Nil Nil Nil
7c −0.74 −0.28 −0.15 −0.58 0.23 0.43 −24.68 0.42 −20.28 0.097 82.70 Nil Nil Nil Nil
7d −0.31 0.04 −0.03 −0.90 0.07 0.31 −21.99 0.47 −14.98 0.097 78.22 Nil Nil Nil Nil
7e −0.32 0.09 0.05 −0.32 0.16 0.28 −30.14 0.44 −22.08 0.098 98.84 Nil Nil Nil Nil
7f −0.51 −0.09 −0.12 −0.20 −0.01 0.16 29.73 0.27 −25.02 0.099 97.07 Nil Nil Nil Nil
7g −0.72 −0.33 −0.17 −0.50 0.14 0.25 −31.23 0.39 −24.93 0.099 100.91 Nil Nil Nil Nil
7h −0.34 −0.04 −0.05 −0.75 0.01 0.16 −28.52 0.46 −26.53 0.098 95.14 Nil Nil Nil Nil
7i −0.02 0.11 0.27 −0.15 0.32 0.32 −24.92 0.43 −13.78 0.094 123.59 Nil Nil Nil Nil
7j −0.20 −0.06 0.12 −0.05 0.17 0.21 −24.56 0.27 −18.60 0.096 121.20 Nil Nil Nil Nil
7k −0.42 −0.27 0.04 −0.34 0.29 0.28 −26.17 0.37 −18.06 0.096 121.22 Nil Nil Nil Nil
7l −0.04 −0.01 0.18 −0.54 0.19 0.21 −23.42 0.45 −19.49 0.094 122.26 Nil Nil Nil Nil
aGPCRL: G protein-coupled receptor ligand; ICM: ion channel modulator; KI: kinase inhibitor; NRL: nuclear receptor ligand; PI: protease
inhibitor; EI: enzyme inhibitor; H.E.: hydration energy (kcal/mol); G.E.: gradient energy (kcal/molA°); T.E.: total energy (kcal/mol); Mut:
mutagenic; Tum: tumorigenic; Irrit: irritant; and R.E.: reproductive effect.
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4.28 (s, 1H, H-10), 7.14 (d, 1H, H-7), 7.93 (d, 1H, H-6), 7.98
(s, 1H, H-4) ppm; 13C NMR (100 MHz, DMSO-d6) δ: 63.2
(C-3), 116.9 (C-7), 123.8 (C-6), 124.4 (C-4), 130.7 (C-8),
140.5 (C-5), 162.4 (C-9), 164.6 (C-11), 184.5 (C-13) ppm;
31P NMR (160 MHz, DMSO-d6) δ: 17.36 ppm. ESI MS m/z:
692.8 [2 M + H]+, 346.9 [M + H]+; anal. calcd for
C9H7N4O5PS2: C, 31.22; H, 2.04; N, 16.18. Found: C,
31.01; H, 1.99; N, 16.13.
2-Hydroxy-5-nitro-3-(1H-1,2,4-triazol-3-ylamino)-2,3-di-
hydro-1,2λ5-benzoxaphosphol-2-one (4h). Yellow solid,
yield: 82.4%, mp: 227−229 °C; IR (ZnSe) ν (cm−1): 1094
(P−O), 1233 (PO), 3431 (N−H); 1H NMR (400 MHz,
DMSO-d6) δ: 7.64 (s, 1H, H-14), 3.98 (s, 1H, H-3), 4.25 (s,
1H, H-10), 7.14 (d, 1H, H-7), 7.92 (d, 1H, H-6), 7.98 (s, 1H,
H-4), 12.95 (s, 1H, C14-NH) ppm;
13C NMR (100 MHz,
DMSO-d6) δ: 63.6 (C-3), 116.5 (C-7), 124.3 (C-6), 124.7 (C-
4), 130.4 (C-8), 140.3 (C-5), 146.5 (C-14), 162.3 (C-9), 163.4
(C-11) ppm; 31P NMR (160 MHz, DMSO-d6) δ: 17.45 ppm;
ESI MS m/z: 298.3 [M + H]+, 598.6 [2 M + H]+; anal. calcd
for C9H8N5O5P: C, 36.38; H, 2.71; N, 23.57, Found: C, 36.14;
H, 2.67; N, 23.42.
6-(Diethylamino)-2-hydroxy-3-(1,3-thiazol-2-ylamino)-
2,3-dihydro-1,2λ5-benzoxaphosphol-2-one (4i). Lavender
solid, yield: 75.3%, mp: 307−309 °C; IR (ZnSe) ν (cm−1):
1095 (P−O), 1231 (PO), 3423 (N−H); 1H NMR (400
MHz, DMSO-d6) δ: 1.24 (t, 6H, 2 × N-CH2CH3), 3.60 (q,
4H, 2 × N-CH2CH3), 3.98 (s, 1H, H-3), 4.24 (s, 1H, H-10),
6.18 (s, 1H, H-7), 6.24 (d, 1H, H-13), 6.78 (d, 1H, H-13),
6.89 (d, 1H, H-4), 7.24 (d, 1H, H-14) ppm; 13C NMR (100
MHz, DMSO-d6) δ: 12.7 (2 × N-CH2-CH3), 44.2 (2 × N-
CH2-CH3), 64.5 (C-3), 98.6 (C-7), 105.8 (C-5), 112.4 (C-13),
119.3 (C-8), 129.5 (C-4), 137.5 (C-14), 149.4 (C-6), 156.7
(C-9), 163.8 (C-11) ppm; 31P NMR (160 MHz, DMSO-d6) δ:
18.25 ppm; ESI MS m/z: 679.4 [2 M + H]+, 340.2 [M + H]+;
anal. calcd for C14H18N3O3PS: C, 49.55; H, 5.35; N, 12.38.
Found: C, 49.30; H, 5.29; N, 12.27.
6-(Diethylamino)-2-hydroxy-3-(1,3,4-thiadiazol-2-ylami-
no)-2,3-dihydro-1,2λ5-benzoxaphosphol-2-one (4j). Pale
pink solid, yield: 72.1%, mp: 256−258 °C; IR (ZnSe) ν
(cm−1): 1082 (P−O), 1238 (PO), 3423 (N−H); 1H NMR
(400 MHz, DMSO-d6) δ: 1.23 (t, 6H, 2 × N-CH2CH3), 3.55
(q, 4H, 2 × N-CH2CH3), 3.93 (s, 1H, H-3), 4.25 (s, 1H, H-
10), 6.16 (s, 1H, H-7), 6.24 (d, 1H, H-13), 6.92 (d, 1H, H-4),
9.18 (s, 1H, H-13) ppm; 13C NMR (100 MHz, DMSO-d6) δ:
12.7 (2 × N-CH2-CH3), 47.2 (2 × N-CH2-CH3), 74.4 (C-3),
98.8 (C-7), 105.2 (C-5), 119.3 (C-8), 129.4 (C-4), 149.5 (C-
6), 152.3 (C-13), 156.6 (C-9), 164.5 (C-11) ppm; 31P NMR
(160 MHz, DMSO-d6) δ: 18.32 ppm; ESI MS m/z: 683.8 [2
M + H]+, 341.4 [M + H]+; anal. calcd for C13H17N4O3PS: C,
45.88; H, 5.03; N, 16.46. Found: C, 45.31; H, 4.99; N, 16.31.
6-(Diethylamino)-2-hydroxy-3-[(5-sulfanyl-1,3,4-thiadia-
zol-2-yl)amino]-2,3-dihydro-1,2λ5-benzoxaphosphol-2-one
(4k). Yellow solid, yield: 67.8%, mp: 172−174 °C; IR (ZnSe) ν
(cm−1): 1096 (P−O), 1235 (PO), 3428 (N−H); 1H NMR
(400 MHz, DMSO-d6) δ: 1.28 (t, 6H, 2 × N-CH2CH3), 3.62
(q, 4H, 2 × N-CH2CH3), 3.98 (s, 1H, H-3), 4.25 (s, 1H, H-
10), 6.18 (s, 1H, H-7), 6.24 (d, 1H, H-13), 6.92 (d, 1H, H-4),
13.16 (s, 1H, C13-SH) ppm;
13C NMR (100 MHz, DMSO-d6)
δ: 12.9 (2 × N-CH2-CH3), 47.4 (2 × N-CH2-CH3), 74.3 (C-
3), 98.7 (C-7), 105.6 (C-5), 119.4 (C-8), 129.5 (C-4), 149.2
(C-6), 156.6 (C-9), 164.5 (C-11), 184.4 (C-13) ppm; 31P
NMR (160 MHz, DMSO-d6) δ: 18.67 ppm; ESI MS m/z:
746.1 [2 M + H]+, 373.5 [M + H]+; anal. calcd for
C13H17N4O3PS2: C, 41.93; H, 4.60; N, 15.04. Found: C,
41.63; H, 4.54; N, 14.88.
6-(Diethylamino)-2-hydroxy-3-(1H-1,2,4-triazol-3-ylami-
no)-2,3-dihydro-1,2λ5-benzoxaphosphol-2-one (4l). Pale yel-
low solid, yield: 70.4%, mp: 259−261 °C; 1H NMR (400
MHz, DMSO-d6) δ: 1.24 (t, 6H, 2 × N-CH2CH3), 3.55 (q,
4H, 2 × N-CH2CH3), 3.98 (s, 1H, H-3), 4.24 (s, 1H, H-10),
6.16 (s, 1H, H-7), 6.24 (d, 1H, H-13), 6.92 (d, 1H, H-4), 7.55
(s, 1H, H-14), 13.48 (s, 1H, C14-NH) ppm;
13C NMR (100
MHz, DMSO-d6) δ: 12.6 (2 × N-CH2-CH3), 47.5 (2 × N-
CH2-CH3), 74.6 (C-3), 98.4 (C-7), 105.6 (C-5), 119.4 (C-8),
129.5 (C-4), 146.3 (C-14), 149.4 (C-6), 156.8 (C-9), 163.4
(C-11) ppm; 31P NMR (160 MHz, DMSO-d6) δ: 19.56 ppm.
IR (ZnSe) ν (cm−1): 1076 (P−O), 1222 (PO), 3433 (N−
H); ESI MS m/z: 647.8 [2 M + H]+, 324.4 [M + H]+; anal.
calcd for C13H18N5O3P: C, 48.30; H, 5.61; N, 21.66. Found: C,
48.02; H, 5.55; N, 21.53.
Cytotoxicity Assay. Pancreatic cancer cell lines of the
study were acquired from the American Type Culture
Collection (ATCC, Manassas, VA) and cultured in an
RPMI-1370 medium, supplemented with FBS (10%) and
penicillin/streptomycin (100 units/mL) at 37 °C. Cells were
plated with a starting density of 105 cells onto a 96-well plate
and treated with title compounds of different concentrations
for a period of 48 h, and cell proliferation by MTT assay was
measured by taking absorbance at 570 nm by a kinetic
microplate reader (BioTek, Winooski, Vermont) on after
incubating for a period of 48 h of the logarithmically grown
cells.
S Phase Cell Cycle Arrest. Initially, the BxPC-3 cells were
subjected for tissue culture and plated on to a 60 × 15 dish
with 5 × 105 cells/dish density and allowed to stand overnight.
Then, the cells were treated with a test solution of 4a, 4b, and
4k with 50 μM concentration and stand for 48 h and then
performed the cell cycle analysis, and FACS (fluorescence
activated cell sorter) was used to perform the study. To
perform the DNA content analysis, the cells were cultured
followed by suspension in 0.5 mL of phosphate buffered saline
(PBS) at 4 °C temperature in an ice bath of 70% ethanol and
cooled for 2 h. Then, the cells were rehydrated in PBS and
then treated with RNase (10 mg/mL) for 30 min, and then the
cells were incubated in the dark for 10 min in propidium
iodide (10 μg/mL) solution. Cell analysis in a FACS analyzer
was performed at 488 nm of excitation wavelength and 585 nm
of emission wavelength. Ultimately, the percentage of cells
existing in cell cycle was predicted by using Flow Jo (BD
biosciences, Rockville, MD) software.
Molecular Docking Studies. The models were prepared
by MOE software and predicted the molecular descriptor
values. The three-dimensional protein structure of a human
ribonucleotide reductase enzyme was granted from the PDB
(Protein Data Bank) database52 and loaded onto the MOE
tool and removed the water molecules and other heteroatoms
and added the polar hydrogens. Then, the three-dimensional
structure was protonated in the solvated environment at 300 K
temperature and 7.0 pH and 0.1 salt concentration conditions
and then applied the electrostatic potential to the system with
1.5 A° cutoff and 1 unit of dielectric constant values. The
Lennard Jones form of van der Waals interactions includes the
attractive form of energy at 8 A° of applied cutoff. After the
protonation, its complete energy minimized structure was
obtained at 0.05 A° of gradient cutoff in AMBER99 force field.
Then, the molecular dynamics simulations studies were
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performed at 300 K temperature for a duration of 10 ps. The
complete simulations were performed for 2000 ps duration
with 0.001 of time step and 0.2 ps of temperature relaxation
time. The significant parameters like velocity, position, and
acceleration were recorded for every 0.5 ps. The three-
dimensional energy minimized structures of the interacted
ligands were constructed in the MOE working environment.
MMFF94x force fields were encompassed, and the related
potential energy terms were empowered for all the van der
Waals interactions, electrostatic interactions, bonded inter-
actions, and restraints with an 8−10 units of enabled cutoff
value for the non-bonded interactions. The comprehensive
born implicit salvation model was enabled by fixing the other
parameters. During the calculation of the parameters, the force
field partial charges were enabled and with 0.05 of fixed
gradient during the minimization process. The molecular
dynamics simulations were performed in the Nose−́Poincare−́
Andersen (NPA) formulation algorithm. The initial fixed run
time temperature (30 K) was increased to 300 K and 0 ps of
heat and cool times.
ADMET Properties. The ADMET properties of com-
pounds 4a-l like were calculated on the preADMET online
server.53−56 In such, the in vitro Caco-2 cell permeability,
percentage of human intestinal absorption (% HIA), in vitro
Madin−Darby Canine Kidney (MDCK) cell permeability, in
vivo blood−brain barrier (BBB) penetration, and in vitro
plasma protein binding (PPB) properties were predicted and
cognized the ADMET potentialities. Similarly, the toxicity
properties like mutagenic, tumorigenic, reproductive, and
irritant effects were also predicted. In such, the robust BBB
penetrability property of a compound under study helps to
decide its ability to be carried in an administered route into the
bloodstream and to govern its CNS (central nervous system)
activity as such the CNS active compounds have the BBB
penetration rate greater than 0.40 and CNS inactive
compounds have the BBB penetration rate less than 0.40.
Similarly, the Caco-2 cell permeability helps in deciding the
capability of Caco-2 cells associating with the intestinal
epithelium system in the multiple drug transport pathways
like transcellular, paracellular, and active efflux ones. Similarly,
the in vitro Caco-2 cell permeability helps in deciding a
compound’s permeability as the permeability value less than 4
indicates that the compounds are poorly permeable, perme-
ability value in the range of 4−70 indicates the compounds are
moderately permeable, and permeability value greater than 70
indicates the compounds are greatly permeable and hence
decides its transportability in cellular and biochemical
processes. Likewise, the extent of PPB reveals us the quantity
of the unbound compound that is distributed in the body
tissues. The percentage of PPB that is greater than 90 indicates
the compounds as strongly bound, and the percentage of PPB
that is less than 90 indicates the compounds as weakly bound
to the tissues and hence denotes its efficacy. In addition, the in
vitroMDCK permeability categorizes the compounds as poorly
permeable if the permeability value is less than 25, and
moderately permeable if the value is in the range of 25−500,
and greatly permeable if the value is greater than 500 and
hence decides their permeable potentiality. Similarly, the
percentage of HIA designates the percentage of an orally
administered compound in hepatic portal vein and is calculated
from the ratio of cumulative excretion in bile, feces, and urine.
Ultimately, it decides the analytes as poor absorbing if the
value is less than 20, moderately absorbing if the value is in the
range of 20−70, and worthy absorbing if the value is greater
than 70 into the human intestine. Similarly, the toxicology
study discloses that the negative toxicology of a molecule
under examination designates it as prone to carcinogenicity
and human ether-a-go-go-related gene (HERG) channel
inhibition and mutagenicity and ultimately supports as a
safer drug.
QSAR Studies. Drugs under investigation with agreeable
ADMET properties will be extended for clinical studies for
worthy oral bioavailability as understood from the assurance of
their solubility and partitioning properties. It includes the
authentication of Lipinski’s rule of five57 in ascertaining the
molecule’s potentiality such as molecular weight (≤500 da),
number of hydrogen bond acceptors (≤10), number of
hydrogen bond donors (≤5), logP (≤5, partition coefficient
in octanol/water), and molar refractivity (40−130) and hence
predicted the Lipinski parameters for 4a−l. Furthermore, the
Veber parameters like total polar surface area and number of
rotatable bonds in addition to Lipinski’s rule are predicted
online with Molinspiration,58 robust software that helps in
computing significant molecular properties of organic com-
pounds with structural sensitivity. The additional parameters
like solubility, number of hydrophobic atoms, density, van der
Waals volume, percentage of absorption, and calculated
partition coefficient (octanol to water) have been predicted.59
Bioactivity and Toxicity Risk Studies. The QSAR
descriptors were evaluated on Molinspiration engine
v2018.10, and bioactivity properties were evaluated on
Molinspiration engine v2018.03 on the Molinspiration online
server.58 The GPCRL, ICM, KI, and NRL interactions, PI and
EI properties, drug-likeness, and drug scores evaluated have
evidenced them as safer drugs. Similarly, the drug properties
and toxicity risks were predicted online by the Osiris property
explorer.60 In consolidation, it assisted in assessing their
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